BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pose E, Coll M, Martínez-Sánchez C, Zeng Z, Surewaard BGJ, Català C, Velasco-de Andrés M, Lozano JJ, Ariño S, Fuster D, Niñerola-Bazán A, Graupera I, Muñoz É, Lozano F, Sancho-Bru P, Kubes P, Ginès P. Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections. Hepatology 2021;74:296-311. [PMID: 33219516 DOI: 10.1002/hep.31644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Marjot T, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW, Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol 2021;18:348-64. [PMID: 33692570 DOI: 10.1038/s41575-021-00426-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
2 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Reference Citation Analysis]
3 Singanayagam A, Triantafyllou E. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Front Immunol 2021;12:661182. [PMID: 33868313 DOI: 10.3389/fimmu.2021.661182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Tranah TH, Kronsten VT, Shawcross DL. Implications and Management of Cirrhosis-Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transpl 2021. [PMID: 34738724 DOI: 10.1002/lt.26353] [Reference Citation Analysis]